Article | May 13, 2025

Developing Drugs For Rare Diseases: A New Approach To Generating Clinical Evidence

Source: DIA

By Janet Woodcock, former director, Center for Drug Evaluation and Research (CDER), US FDA

GettyImages-1403976499 vaccine, development

The past half-century has witnessed remarkable progress in biomedical research, unraveling the complexities of human disease and offering new therapeutic possibilities. For rare diseases, this progress has been particularly significant, with researchers identifying the molecular basis of many conditions and developing potential treatments. While the path to drug approval is complex, especially for rare diseases, innovative solutions are within reach. This article addresses the limitations of applying standard clinical trial designs to rare disease drug development and proposes alternative approaches to generating robust evidence of efficacy.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader